Free public records show Genrix (Shanghai) Biopharmaceutical Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Genrix (Shanghai) Biopharmaceutical Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
14 active studies led by Genrix (Shanghai) Biopharmaceutical Co., Ltd., of 28 in all
Source: ClinicalTrials.gov, Studies with Genrix (Shanghai) Biopharmaceutical Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Genrix (Shanghai) Biopharmaceutical Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Genrix (Shanghai) Biopharmaceutical Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Genrix (Shanghai) Biopharmaceutical Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Genrix (Shanghai) Biopharmaceutical Co., Ltd. is in.
Stories on the topics Genrix (Shanghai) Biopharmaceutical Co., Ltd. works in.
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Plastic surgeons performed more than 19.1 million non-surgical aesthetic procedures in 2023. Hair removal and…
ReadSearch all reports for Genrix (Shanghai) Biopharmaceutical Co., Ltd. All companies